Despite warnings, and a number of close calls, drugmakers failed to develop and stockpile drugs to fight a viral pandemic. Now, in the wake of SARS-CoV-2, they are pledging not to make the same mistake again.
Around the world, researchers are racing to develop drugs to target COVID-19, but also broad-spectrum antivirals that could be used to treat future viral threats.